Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06788509 | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring | enrolling by invitation | Phase 1 | 120 | Janssen Research & Development, LLCINDUSTRY |
| 15 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT06169579 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers | enrolling by invitation | Phase 1 | 96 | Shenzhen NewDEL Biotech, Co., LtdINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06987058 | RVU120 Rollover Study(ROVER-01) | enrolling by invitation | Phase 2 | 14 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT02154022 | Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future Toxicity | enrolling by invitation | — | 100 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07659379 | Gotistobart Long Term Extension (LTE) Study | enrolling by invitation | Phase 3 | 20 | OncoC4, Inc.INDUSTRY | 1 | Aug 24, 2026 | clinicaltrials |
| NCT06630351 | Group Meaning-Centered Psychotherapy for the Improvement of Wellbeing in Caregivers of Patients With Serious Illness | enrolling by invitation | N/A | 80 | Mayo ClinicOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05600933 | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | enrolling by invitation | — | 1,200 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07741006 | Clinical Evaluation of [68Ga]Ga-ELI411 PET Imaging in Adult Patients With Solid Tumors | enrolling by invitation | Early Phase 1 | 18 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06767475 | Mindfulness-Based Stress Reduction to Improve Well-being in Black Adult Cancer Survivors, Community Faith-based Mindfulness Ministry(ComFaMM) | enrolling by invitation | N/A | 65 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02315599 | Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials | enrolling by invitation | — | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07307833 | Impact of Immunotherapy on Vestibular Function, The Mayo Clinic Arizona Experience | enrolling by invitation | — | 50 | Mayo ClinicOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT00900497 | A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers | enrolling by invitation | Phase 1 / Phase 2 | 29 | Dipnarine MaharajOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07215039 | Improving Prison Health Equity Through Cancer Literacy and Screening Awareness in Florida | enrolling by invitation | — | 1,200 | Mayo ClinicOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07225920 | Understanding Needs of Older Patients Prior to Starting Cancer Treatment(PGA) | enrolling by invitation | N/A | 216 | Wake Forest University Health SciencesOTHER | 2 | Apr 8, 2026 | clinicaltrials |
| NCT06215846 | A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors | enrolling by invitation | Phase 1 | 12 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | enrolling by invitation | Phase 1 | 54 | PharmaEssentiaINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 30 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT06925685 | Follow-Up for Study Participants Treated With an Allogeneic CAR T-Cell Product | enrolling by invitation | — | 50 | Allogene TherapeuticsINDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT04762862 | QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy(QUANTACT) | enrolling by invitation | — | 1,200 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04260269 | Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity Study(CardioSwitch) | enrolling by invitation | — | 200 | Helsinki University Central HospitalOTHER | 7 | Dec 12, 2024 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials